Keytruda (pembrolizumab) is an immune checkpoint inhibitor used to treat various types of cancer, including melanoma, non-small cell lung cancer, and head and neck squamous cell carcinoma [1]. While Keytruda has been shown to be effective in treating cancer, there are potential long-term side effects that patients should be aware of.

According to a recent article by the National Cancer Institute, long-term use of immune checkpoint inhibitors like Keytruda can lead to immune-related adverse events (irAEs) [2]. These side effects can affect various organs in the body, including the lungs, liver, and endocrine system. Some of the most common irAEs associated with Keytruda use include hypothyroidism, pneumonitis, and colitis. However, these side effects are generally manageable with proper medical care.

Another article by GoodRx states that while the long-term side effects of Keytruda are not fully understood, studies have shown that some patients may experience autoimmune disorders, such as lupus or rheumatoid arthritis, as a result of treatment with immune checkpoint inhibitors [3]. It is important for patients to report any new or worsening symptoms to their healthcare provider, as early detection and treatment can help prevent serious complications.

In conclusion, while Keytruda has been shown to be effective in treating cancer, there are potential long-term side effects that patients should be aware of. These side effects can affect various organs in the body, and some patients may develop autoimmune disorders as a result of treatment with immune checkpoint inhibitors. It is important for patients to report any new or worsening symptoms to their healthcare provider, as early detection and treatment can help prevent serious complications.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA
[2] https://www.cancer.gov/news-events/cancer-currents-blog/2021/immune-checkpoint-inhibitors-melanoma-long-term-side-effects
[3] https://www.goodrx.com/pembrolizumab/long-term-effects-of-keytruda